CLINICAL TRIALS PROFILE FOR AZACTAM
✉ Email this page to a colleague
All Clinical Trials for Azactam
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02730793 ↗ | Aztreonam Aerosol to Treat Cystic Fibrosis Nasal Disease | Terminated | Eastern Virginia Medical School | Phase 2 | 2017-01-01 | This study is designed as a masked, two center, randomized, placebo-controlled pilot study to evaluate the safety and efficacy of nasal and oral inhalation of 75 mg aztreonam in subjects with CF and lung infection due to PA. The study will involve two sites: Virginia Commonwealth University Medical Center (VCU) and Eastern Virginia Medical School (EVMS). Potential subjects will be identified in each site's CF clinic. |
| NCT02730793 ↗ | Aztreonam Aerosol to Treat Cystic Fibrosis Nasal Disease | Terminated | Virginia Commonwealth University | Phase 2 | 2017-01-01 | This study is designed as a masked, two center, randomized, placebo-controlled pilot study to evaluate the safety and efficacy of nasal and oral inhalation of 75 mg aztreonam in subjects with CF and lung infection due to PA. The study will involve two sites: Virginia Commonwealth University Medical Center (VCU) and Eastern Virginia Medical School (EVMS). Potential subjects will be identified in each site's CF clinic. |
| NCT03978091 ↗ | A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | 2019-07-09 | This is a Phase I, open-label, non-randomized, single center study in 48 healthy adult male and female subjects, aged 18 to 45 years. This study is aimed to investigate the safety and pharmacokinetics of ceftazidime-avibactam (AVYCAZ) combined with aztreonam (ATM), AVYCAZ alone, and ATM alone. The study will have 6 arms, arms 1-4 are the single drug administration treatment groups and will include AVYCAZ per label dosing, AVYCAZ as a continuous infusion (CI), ATM per label dosing, and ATM as a CI. Arms 5 and 6 are the two AVYCAZ and ATM combination drug administration treatment groups. The duration of subject participation will be up to 44 days, and the total length of the study will be 15 months. The primary objective of this study is to describe the safety of two dosing regimens of AVYCAZ combined with ATM relative to AVYCAZ alone, and ATM alone in healthy adult subjects. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Azactam
Condition Name
Clinical Trial Locations for Azactam
Trials by Country
Clinical Trial Progress for Azactam
Clinical Trial Phase
Clinical Trial Sponsors for Azactam
Sponsor Name
